Stock Price & Analysis

The S1 support level for AVTX Stock is $6.17 ,The R1 resistant level for AVTX Stock is $7.68.

As of the end of day on 2025-01-23, the price of AVTX Stock was $7.69.

The target price for AVTX Stock according to analyst rating is 33.00, with the highest price target at 40.00 and the lowest at 24.00. Analysts have a Strong Buy rating on AVTX Stock overall.

The market cap of AVTX is $78.8M.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-002) (anti-LIGHT monoclonal antibody (mAb)) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Quisovalimab shows reduction of Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT) levels, as well as a favorable safety and tolerability profile, in all indications studied including COVID-19 acute respiratory distress syndrome (ARDS), Crohn's Disease, and non-eosinophilic asthma (NEA).

AVTX has a total of 19 employees.